Yemaachi Biotech today announced that a diverse group of worldwide scientists, led by visionary cancer genomics researcher Melissa B. Davis, PhD, has received a prestigious Cancer Grand Challenges award of up to $25 million over five years. The collaboration, including Yemaachi CEO & Co-founder Yaw Bediako, PhD, aims to advance equity in cancer research, screening, diagnosis, and outcomes on a global scale.
“It is an immense honor to partner with Dr. Davis and this coalition of collaborators from various disciplines and regions,” said Bediako. “We fully believe that this meaningful work will yield impactful innovations to benefit cancer patients everywhere, regardless of circumstances. I am incredibly proud that our dedication to scientific excellence and commitment to serving under served populations have earned Team SAMBAI’s trust and support for our joint mission ahead.”
Also Read- Experts Recommend This Warren Buffett-Owned ETF for Everyday Investors
Due to inequalities in many areas including cancer prevention, screening, diagnosis, treatment and research, cancer incidence and mortality exhibit disparities which are a crucial public health problem. By evaluating an extensive collection of patient data, the SAMBAI team has discovered several factors that lead to disparate cancer outcomes in under served populations; its research is focused on these communities and entirely applicable to such health problems as breast, prostate and pancreatic cancer in people of African descent. The SAMBAI research and bio bank will encompass full measurement of social, environmental, genetic, and biological shaped facts, all of which can be used for analyzing and dissolving cancer inequities.
“Diversifying cancer genomics and research is essential in order to achieve better results. Team SAMBAI is helping make precision medicine suitable for underrepresented communities everywhere, and for all patients,” he said.
Cancer Grand Challenges is a global funding initiative which was setup with the support of Cancer Research UK and the National Cancer Institute in the US to the fuse innovative, multifaceted groups together, think differently and take on cancer’s strongest challenge.
About Yemaachi
Yemaachi is generating harnessing the world’s largest cancer bio-database. To develop cancer diagnostics and drugs that not only work for one group of people but many different groups globally, Our goal is both to save lives around the world and to foster the welfare of those who take part in or support our activities. Yemaachi envisages a future in which that features African genomic diversity, as well as insights and expertise, becomes an integral part of precision oncology research, diagnostics and therapeutics everywhere for the benefit of patients.
Also Read- Rupert Murdoch Announces Engagement for the Sixth Time in 92
About Cancer Grand Challenges
Cancer Grand Challenges was launched in 2020 with a lofty vision – to unite the top thinkers across disciplines and borders in pursuit of conquering cancer’s most vexing mysteries. Funded by Cancer Research UK and the US National Cancer Institute, two heavyweights in the fight against the disease, this initiative aims to rally a diverse collective of experts. Together, they will reimagine approaches and attack problems too complex for any one researcher, lab or country to crack alone. With grants up to $25 million, teams supported by Cancer Grand Challenges will break free of traditional constraints. Unfettered by the limitations of their usual peers or locations, these collaborative forces will be empowered to generate discoveries at an accelerated pace. It is the progress so urgently needed that only such borderless, outside-the-box thinking can achieve.
About Team SAMBAI
Team SAMBAI has set an ambitious goal – to create an unprecedented resource, the SAMBAI Biobank and Data Repository for Cancer Equity Research. This repository aims to uncover the complex factors that drive disparate cancer outcomes in diverse underserved populations. Specifically, the team will focus on breast, prostate and pancreatic cancer in people of African descent. Leading the charge is Dr. Melissa B. Davis, Director of the Institute of Translational Genomic Medicine at Morehouse School of Medicine. Her visionary leadership guides the team towards answering critical questions about cancer inequalities. With rigorous studies testing hypotheses using the unparalleled datasets, they hope to generate global actions to overcome inequitable cancer burdens. Supported by grants from Cancer Research UK and the National Cancer Institute, Team SAMBAI is determined to produce international collaborations. These partnerships will clarify research and ultimately help affected communities worldwide.
